N/A N=203 Microalbuminuria in Children With and Without Diabetes
Diabetes Mellitus
Primary: Number of Subjects With Normal Urinary Protein Excretion in Healthy and Diabetic Children, Assessed Over 1 Day. — 91; 112 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=130 Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria
Diabetic Kidney Disease
Primary: Changes in Log-transformed Urinary Albumin-to-creatinine Ratio (UACR) at Week 12 — -0.10; -0.15; -0.53 Log(mg/g) — p=0.7953
Phase 2 N=154 A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
Chronic Kidney Disease · Type 2 Diabetes Mellitus
Primary: Changes in Urine Albumin to Creatinine Ratio (UACR) — -64.6; 104.8 mg/g — p=0.279
Phase 3 N=45 Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
Edema · Hypoproteinemia
Primary: Ventilator-free Days — 4; 13 days
N/A N=1,537 Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
Type 2 Diabetes Mellitus
Primary: Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and…
N/A N=44 A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Alport Syndrome · Kidney Disease
Primary: Number of Subjects Developing Microalbuminuria During Study Period — 35 Participants
Phase 2 N=34 Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
Diabetic Nephropathy
Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change
Phase 4 N=28 Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g
Phase 4 N=63 Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Idiopathic Focal Segmental Glomerulosclerosis
Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants
Phase 2 N=17 Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
Kidney Disease · Albuminuria
Primary: The Primary Outcome Measure is Level of Albuminuria. — 927.9; 897.1 ratio
Phase 3 N=1,056 Effect of Sulodexide in Early Diabetic Nephropathy
Diabetic Nephropathy
Primary: Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria — 39; 30 Participants
Phase 2 N=60 Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Hyperuricemia · Albuminuria · Type 2 Diabetes
Primary: Urinary Albumin to Creatinine Ratio (UACR) — -48.65; -15.31 Precent change
Phase 2 N=53 Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria
Chronic Kidney Diseases · Proteinuria
Primary: Change in 24-hr Proteinuria With Dapagliflozin for Six Weeks Relative to Placebo in Patients With Non-diabetic Kidney Disease and Proteinuria 500 mg/Day on Stable…
Phase 2 N=281 The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
Diabetic Nephropathy · Chronic Kidney Disease
Primary: Change From Baseline to the Last On-treatment Measurement in Urine Albumin to Creatinine Ratio (UACR) Levels Determined From the First Morning Void (FMV) Urine…
Phase 4 N=45 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
Type 1 Diabetes · Diabetic Nephropathy · Diabetic Kidney Disease
Primary: Change in Urine Uric Acid Concentration (Increased Solubility) by Assay — 23.81; 22.30 mg/dl
Phase 2 N=136 Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Albuminuria Absolute Value and Ratio to Baseline by Study Visit and Treatment Group — 705.72; 696.30; 758.22; 705.29 mg/g — p=1.000
Phase 2 N=10 Aurinia Early Urinary Protein Reduction Predicts Response
Lupus Nephritis
Primary: Number of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR) — 7 Participants
Phase 2 N=237 Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
Hyperlipidemia
Primary: Urinary Protein/Creatinine Ratio at Week 52 [LOCF] — 0.938; 1.082; 0.759 ratio
N/A N=31 Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23
Albuminuria
Primary: 24-hour Urine Albumin Excretion — 86.2; 76.4 mg/day — p=0.05
Phase 3 N=410 Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Phase 4 N=128 ARIA (Atacand Renoprotection In NephropAthy Pt.)
Non-diabetic Nephropathy With Hypertension
Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g
Phase 2 N=353 Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
Diabetes Mellitus
Primary: Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. — 1.016; 0.955; 0.874 mg/g
Phase 2 N=156 A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
Type 2 Diabetes Mellitus With Diabetic Nephropathy
Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs — 24; 21; 22; 6 Participants
N/A N=10 Renal Retention of Microbubbles
- Study Focus: Renal Retention of Lipid Microbubbles
Primary: Renal Video Intensity Units — 19 units on a scale
Phase 4 N=5 Adrenocorticotropic Hormone in Membranous Nephropathy
Membranous Nephropathy
Primary: Change in Proteinuria — 4.56; 1.36 ratio
N/A N=80 Uric Acid and the Endothelium in CKD
Kidney Disease
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47
N/A N=28 Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr
Phase 4 N=237 Shiga Microalbuminuria Reduction Trial-2
Type 2 Diabetes Mellitus · Hypertension
Primary: Reduction in Albuminuria — -5.5; -6.7 percentage of UACR change
Phase 2 N=26 Lowering Serum Uric Acid to Prevent Acute Kidney Injury
Hyperuricemia
Primary: Number of Patients With Acute Kidney Injury (AKI). — 13; 13 Participants
N/A N=110 Restricted Reporting for Positive Urine Cultures
Bacteriuria · Urinary Tract Infection
Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants